検索結果

お知らせ | 千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has developed and obtained appr...

Publications | Research & Development | SENJU Pharmaceutica

and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient receptor potential cation channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satok...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

erica Antagonistic activity and selectivity of SJP-0132 against transient receptor potential cation channel subfamily V member 1 Tomoka Uemura1, Hideharu Uchida2, Chika Higashi2, Ken-ichi Amano2, Atsu...

n Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designed to improve both subjective symptoms and...

n Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designed to improve both subjective symptoms and...